Business
Placing to Raise £451,250 and Director’s Dealing
Placing to Raise £451,250 and Director’s Dealing.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n\n8 May 2025\nTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.\n \nHemogenyx Pharmaceuticals plc\n(\"Hemogenyx Pharmaceuticals\" or the \"Company\")\nHemogenyx Secures £451,250 to continue its Phase 1 Clinical Trials\nAnd\nDirector's Dealing\nIntroduction\nHemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has raised gross proceeds of £451,250 (before expenses) via an allotment to Vladislav Sandler of 250,000 new ordinary shares of £0.01 each (\"New Ordinary Shares\") at an issue price of 180.5p (being the bid price as at close of business on 7 May 2025) (the \"Issue Price\").\nThe net proceeds of this fundraise will be dedicated to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy (\"HG-CT-1\"), aimed at treating relapsed/refractory acute myeloid leukemia in adults (\"R/R AML\"). As shareholders will be aware, the first two patients have now been infused with HG-CT-1.\nIssuance of the New Ordinary Shares\nThe Company is currently unable to issue and admit the New Ordinary Shares without either the publication of an FCA approved prospectus or relying upon an exemption to the requirement to issue a prospectus.\n \nConsequentially, this fundraise involves the acceptance by Vladislav Sandler, CEO and director of the Company to subscribe for the New Ordinary Shares at the Issue Price pursuant to the employee offer exemption under Article 1(4)(i) and 1(5) (h) of the UK Prospectus Regulation.\nFollowing allotment of the New Ordinary Shares, Vladislav Sandler has agreed to direct their issue to an institution, who will immediately sell these New Ordinary Shares at the same Issue Price to a purchaser identified by it (the \"Purchaser\").\nWarrants\nConcurrent with the purchase of the New Ordinary Shares, the Purchaser will receive warrants from the Company on a one-for-one basis. These warrants will be exercisable for a period of 36 months at an exercise price of 270 pence (\"Exercise Price\"), subject to adjustment in certain circumstances as set o...